Clinical Trial Update: IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating IL1RAP-targeting CAR-T cells for relapsed/refractory hepatocellular carcinoma is currently recruiting at Shanghai Zhongshan …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IL1RAP-targeting CAR-T cells (CAR-T cell therapy targeting IL1RAP)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: HCC | Phase 1 | Status: RECRUITING